Pemvidutide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Pemvidutide is an investigational drug with multiple FDA Fast Track Designations (MASH, AUD) and FDA Breakthrough Therapy Designation (MASH), but no approved New Drug Application as of May 2026. Legal access in the United States is restricted to participants in registered clinical trials under IND. It is not compoundable, not available for prescription, and not subject to the FDA-19 Category 2 peptide compounding framework (fda19=false) because it has never been evaluated under the 503A/503B bulk-drug list process.

No verifiable third-party COA path in this market

Transparent blend · bci-1.0 · never paid-placement

Primary name

Pemvidutide

Origin

Pemvidutide (developer code ALT-801; CAS 2243135-08-0; PubChem registration not confirmed) is a synthetic analogue of oxyntomodulin developed by Altimmune. Oxyntomodulin is an endogenous proglucagon-derived peptide secreted by intestinal L-cells that exhibits partial agonist activity at both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Pemvidutide incorporates amino-acid modifications relative to native oxyntomodulin to achieve balanced (approximately 1:1) full agonism at both receptors, and a proprietary EuPort domain — a glycolipid surfactant conjugate attached to the peptide — that extends its plasma half-life and slows absorption from the subcutaneous injection site, enabling once-weekly dosing and potentially reducing peak-concentration-related gastrointestinal side effects. Registry identity details (PubChem CID, InChI key, confirmed sequence) are not yet publicly available; identity completeness is marked manual_pending.

Appearance

Presumed white to off-white lyophilised powder, typical for lipid-conjugated peptides of this molecular weight; no confirmed vendor or manufacturer description available for research-grade material as of May 2026

Solubility

Expected to be soluble in aqueous buffered media at physiological pH; EuPort gly…

Sequence not available in current seed.

Stability: EuPort glycolipid surfactant conjugation is reported to extend plasma half-life and reduce susceptibility to peptidase degradation; standard degradation pathway

Vial sizes

null mg

Purity grades

research grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Pemvidutide simultaneously activates the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR), both class B G-protein-coupled receptors that signal primarily through Gs/cAMP pathways
• GLP-1R engagement in pancreatic beta cells potentiates glucose-dependent insulin secretion, suppresses glucagon release from alpha cells, slows gastric emptying, and activates hypothalamic and brainstem satiety circuits that reduce caloric intake
• GCGR engagement in hepatocytes stimulates fatty acid oxidation and glycogenolysis, reduces hepatic lipid accumulation, and elevates resting energy expenditure — effects largely absent from selective GLP-1R agonists
• The balanced 1:1 GLP-1R/GCGR potency ratio is intended to maximise both appetite suppression and energy expenditure while the EuPort conjugation mitigates peak-concentration-driven gastrointestinal intolerance by reducing the rate of entry into the systemic circulation relative to its overall exposure

Pharmacokinetics (ADME)

Half-life

Not precisely characterised in publicly available data; EuPort glycolipid conjugation is designed to extend half-life sufficiently to support once-weekly subcutaneous dosing, consistent with a half-life of approximately one week, though a specific numerical value has not been confirmed in published PK reports as of May 2026.

Clearance

Not reported in publicly available sources as of May 2026.

PK–PD note: A dedicated drug–drug interaction study was conducted in healthy volunteers (NCT04972396, Phase 1, completed). Pemvidutide's EuPort technology is reported to produce slower kinetics of entry into the …

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Abdu E, Alessa A, Al-Murdhimah A. Efficacy and Safety of Pemvidutide in Patients with MASH: A Systematic Review and Dose-Specific Meta-Analysis of RCTs. medRxiv preprint (PROSPERO CRD420251270536) — Preprint; 3 RCTs / 370 participants; primary outcomes LFC and ELF score
• Efficacy and safety of pemvidutide in MASH: a GRADE-assessed meta-analysis of RCTs. Naunyn-Schmiedeberg's Arch Pharmacol
• Tacke F. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet. 2025;406(10520):2604-2606 (editorial commentary)
• Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025;187:171380

5 registered trials — 0 currently recruiting.

Phase 1
NCT04972396
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

COMPLETED

Phase 1
NCT05006885
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

COMPLETED

Phase 1
NCT04561245
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

COMPLETED

Phase 2
NCT05989711
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

COMPLETED

Phase 1
NCT05292911
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

COMPLETED

Summary (literature)

Across Phase 1 and Phase 2 trials, the most frequently reported adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These were predominantly mild to moderate in severity and largely transient. In the MOMENTUM obesity trial at 2.4 mg, rates of adve…

WADA status

Not specifically listed by name on the 2026 WADA Prohibited List. GLP-1 receptor agonists as a class are not currently prohibited in sport. The glucagon recepto…

Dominant research route: Subcutaneous (SC) — once-weekly injection is the sole route studied across all reported Phase 2 trials

Once-weekly subcutaneous administration studied in human Phase 2 RCTs (MOMENTUM obesity trial N=391; IMPACT MASH Phase 2b; 12- and 24-week MASLD trials) at 1.2, 1.8, and 2.4 mg doses in adults

Bioavailability: Subcutaneous route used in all reported clinical trials; no oral/IV/IM bioavailability data published in retrieved sources. Peptide administered without dose titration in IMPACT trial.

All identified human clinical studies of pemvidutide (Phase 2 RCTs in obesity/MOMENTUM, MASLD, and MASH/IMPACT) administered the drug as a once-weekly subcutaneous injection. No alternative routes (oral, IV, IM, intranasal, topical) were described in the retrieved primary literature.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

What each test proves — general guidance, plus this compound's researched purity data

Independent labs cited for this compound

No recalls, seizures, or counterfeit-specific enforcement actions naming pemvidutide were found in FDA warning-letter, recall, or import-alert databases as of search date. Pemvidutide remains an investigational drug with no approved marketed product, so no legitimate drug-product recall pathway exists yet.

Buyer red-flag checklist

• Pemvidutide is an investigational drug (Phase 2b/3) with no FDA approval; any 'for sale' pemvidutide marketed for human use is unregulated and not legitimate medicine.
• Sold as 'research use only' by chemical vendors (e.g., MedChemExpress) despite being a clinical-stage drug candidate — RUO labeling is a known gray-market loophole flagged by FDA.
• FDA Warning Letter to USApeptide.com (Feb 2025) targeted unapproved GLP-1 'research peptides' sold online; pemvidutide belongs to the same GLP-1 agonist class under enforcement scrutiny.
• No independent lab (Janoshik/MZ Biolabs/Finnrick) purity or identity test results were found for pemvidutide, so vendor COAs cannot be independently corroborated.
• Class-wide data: Janoshik Analytical found ~43% of tested research peptides failed to meet label purity claims in 2024; GLP-1 agonists are a high-counterfeit-risk category.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent third-party lab tests (Janoshik, MZ Biolabs, Finnrick) specific to pemvidutide were located. Pemvidutide is sold only as a research-use-only chemical (e.g., MedChemExpress, CAS 2538014-94-5); no published per-batch purity/identity COAs from independent community labs were found for this compound.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not specifically listed on the WADA Prohibited List. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist; related GLP-1 agonists (e.g., semaglutide) are included in WADA's Monitoring Program but are not prohibited. Pemvidutide itself is not named in the 2025 or 2026 Prohibited List.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Heavy retail-investor / shareholder overrepresentation (r/Altimmune, r/wallstreetbets) skews positive
• Investigational asset with no approved commercial supply — most 'experience' reports are trial-derived or speculative, not first-party self-experimentation
• Early-phase (Phase 2) data extrapolated to efficacy/benefit claims
• Mechanism comparisons to other dual/tri-agonists are largely anecdotal and not peer-validated

Manually researched from reddit, x, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Investigational once-weekly GLP-1/glucagon dual receptor agonist (ALT-801) in phase 2b for MASH and phase 2 for obesity and alcohol use disorder. Approximately 12 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Investigational — no FDA approval; no NDA filed. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet